To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

Post Category: Latest News

April 23, 2024
tovorafenib FDA Approval for LGG

(Courtesy of ASCO FDA Alerts) tovorafenib FDA Approval for LGG On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. […]

Read More
January 29, 2024
Revolutionizing Cancer Care: Advances in Radiation Therapy for Brain Tumors

Modern radiation therapy for brain tumors, marked by precision, personalization, safety, and ongoing innovation, holds promise for enhancing patient outcomes and instilling hope in challenging diagnoses.

Read More
December 19, 2023
Empowering Support: Thoughtful Ways to Help and Honor Your Loved Ones during the Festive Season

To truly support your loved ones during their times of need, consider these practical ways to provide help and show your support.

Read More
December 15, 2023
Shuttle Pharma Advances Patient-Centric Breakthrough for Glioblastoma Treatment

Shuttle Pharmaceuticals has submitted a new drug for FDA approval to improve the effectiveness of radiation therapy for GBM patients.

Read More
October 19, 2023
Oncoheroes Gains FDA Approval for Pediatric Cancer Drug Trials

Oncoheroes Biosciences, Inc. has received the FDA's greenlight to proceed with two crucial clinical trials, which open the door to new drug treatments for pediatric cancer .

Read More
October 1, 2023
Innovative Approach in Treating Recurrent Glioma: Insights from the ReSPECT-GBM Trial

186RNL, a rhenium isotope, is studied as a treatment for recurrent glioma. Patients are currently being enrolled in clinical trials.

Read More
October 1, 2023
Loc3CAR Trial: Innovative Treatment Hope for Pediatric CNS Tumors

The Loc3CAR clinical trial is an exciting development in the treatment of pediatric primary central nervous system (CNS) neoplasms.

Read More
September 18, 2023
FDA Widens Temodar's Approval to Fight Another Brain Cancer Type

The FDA expanded use of Temodar to include two new indications for the treatment of adults with anaplastic astrocytoma.

Read More


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram